Biotech Stock Still 700%: What Investors Should Do Today
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
This piece outlines scenarios where a lifecycle fund may be preferable to a target date fund, helping you tailor your retirement strategy.
23,259 articlesA biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
As the Fed signals potential slower rate moves, tech stocks gyrate. The standout is a cash-generating giant deliverin...
Oil trades around the $100 barrel mark as investors seek safety. This piece identifies a top defensive ETF and explai...
As AI stocks drive gains, traders debate whether equal-weighted ETFs like RSP can outpace SPY’s cap-weighted edge. He...
Through the first three months of 2026, the stock market diverged: the S&P 500 fell, while smaller firms outperformed...
Seltz announced a $12.5 million seed round to redefine how AI agents surface information. The funding underscores a g...
As Zymeworks gears up for 2026 earnings, investors should focus on cash runway, pipeline milestones, and collaboratio...
A growing mismatch in mortgage underwriting is leaving many retirees with fewer loan options. New data show denial ra...
Morgan Stanley’s MSBT, the bank’s first spot Bitcoin ETF, has surged to $233 million in AUM in its first month, under...
Bitwise CIO Matt Hougan argues that Strategy's STRC selloff reflects end-of-cycle deleveraging preceding a bitcoin bo...
EDIV has outperformed on yield-focused EM plays, but the next year hinges on the dollar’s next move will drive curren...
Hydrogen names tumble after a monster 2026 run, led by FuelCell Energy, Bloom Energy, and Plug Power. The market back...